Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
1(50.0%)
N/A
1(50.0%)
2Total
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06743828Not ApplicableActive Not Recruiting

Impacts of Fermented Pea- and Legume-based Product on Gut Microbiota and Health

Role: collaborator

NCT05676372Unknown

Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC

Role: collaborator

NCT04326920Phase 4Completed

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

Role: collaborator

All 3 trials loaded